We love to hear from our listeners. Send us a message.

Last October, we dropped an episode dissecting the relationship between Ray Therapeutics and one of its lead funders, 4BIO, and it quickly rocketed to an all-time Business of Biotech fan favorite. This week, we’re doing it again with a candid, behind-the-scenes breakdown of how Vedanta Biosciences secured the support of K2 Health Ventures in its recent $100 million+ financing to fund a pivotal Phase 3 study. Join us as we dissect a story that started when Vedanta CEO Bernat Olle, Ph.D. met K2HV’s Founding Managing Director & CEO Parag Shah on a mountain during the Timmerman Traverse. Their story serves as a guide to ensuring the cultural and strategic alignment of science and finance.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: [email protected]

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/